Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author holds a long position in TEM.
← Back to Free Index

TEM

Analysis as of: 2026-05-28
Tempus AI, Inc.
Healthcare technology company that combines genomic diagnostics, multimodal clinical data, and workflow software to support precision medicine.
ai biotech enterprise healthcare software
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Real data moat, but monetization still matters
The upside case is not a pure AI multiple story. It depends on proving that diagnostics volume can reliably convert into higher-margin data, workflow, and evidence revenue while financing and reimbursement risk steadily fade.

Analysis

Thesis
Tempus can still compound into a much larger precision-medicine platform if it keeps turning each diagnostic interaction and provider integration into governed data, then monetizes that data through higher-margin applications and workflow rails faster than reimbursement and financing drag can cap the story.
Last Economy Alignment
Cheaper cognition makes Tempus' governed multimodal data, provider workflow links, and clinical automation more valuable. It is strongly helped by the Last Economy, but reimbursement, privacy, and trust still gate how much of that value it can capture.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
2.6x (from 5 most recent analyses)
Reasoning
This is still mainly a revenue compounding case, not a heroic re-rating case. The optimistic but disciplined view is that diagnostics keeps expanding, Data & Applications grows faster than the core lab business, and Tempus earns a better mix and cleaner cash profile. If that happens, the business can be worth materially more even with a lower revenue multiple than today because the company would be larger, less financing-constrained, and more software-like in its gross profit mix.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The core risk is economic conversion, not technical existence. Tempus already has real products, real distribution, and a credible data flywheel, but it still must prove that diagnostics volume reliably converts into durable, better-margin data and workflow revenue before reimbursement friction, privacy/trust issues, or renewed financing needs cap the business at a lower-quality multiple.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.59
They control governed patient data, lab output, and provider workflow links, so better AI makes their platform more useful each time another test and data connection is added. The risk is that reimbursement, privacy rules, or EHR-native agents keep the value stuck at the lab layer instead of the software layer.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$67.20
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case